Literature DB >> 10968593

Immunotherapy of gynaecological high-risk human papilloma virus infection with human leukocyte ultrafiltrate.

H Spitzbart1, U B Hoyme.   

Abstract

OBJECTIVE: In this preliminary presentation the outcome of women following systemic treatment of cervical human papilloma virus (HPV) with a leukocyte ultrafiltrate is reported.
METHODS: Cervical brush specimens of 819 women with low-grade CIN-1 were evaluated for HPV infection. HPV-positive patients were treated either by cone biopsy because of suspicious colposcopy or by antibiotics for symptoms of bacterial cervicitis. The remaining women were considered as asymptomatic carriers of HPV and underwent systemic therapy by a human leukocyte ultrafiltrate in a dosage of 5 IE, 6 times in the first 2 weeks, and additionally as a single dose at weeks 4, 6, 8 and 10.
RESULTS: The leukocyte ultrafiltrate was administered to 97 HPV-positive women. In follow-up 88.7% were HPV negative at week 6; the remaining 11 women were tested negative after completion of a second course of therapy.
CONCLUSIONS: These preliminary data on the successful treatment of HPV infection by a leukocyte ultrafiltrate are very promising but have to be supported by additional research.

Entities:  

Mesh:

Year:  2000        PMID: 10968593      PMCID: PMC1784679          DOI: 10.1155/S1064744900000156

Source DB:  PubMed          Journal:  Infect Dis Obstet Gynecol        ISSN: 1064-7449


  12 in total

1.  Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus.

Authors:  L Edwards; A Ferenczy; L Eron; D Baker; M L Owens; T L Fox; A J Hougham; K A Schmitt
Journal:  Arch Dermatol       Date:  1998-01

2.  Prognostic factors in cervical human papillomavirus infections.

Authors:  V Kataja; S Syrjänen; R Mäntyjärvi; M Yliskoski; S Saarikoski; K Syrjänen
Journal:  Sex Transm Dis       Date:  1992 May-Jun       Impact factor: 2.830

3.  Self-treatment using a 0.5% podophyllotoxin cream of external genital condylomata acuminata in women. A placebo-controlled, double-blind study.

Authors:  G von Krogh; D Hellberg
Journal:  Sex Transm Dis       Date:  1992 May-Jun       Impact factor: 2.830

4.  Predictive value of human papillomavirus DNA detection by filter hybridization and polymerase chain reaction in women with negative results of colposcopic examination.

Authors:  G J Nuovo; J Moritz; L L Walsh; P MacConnell; J Koulos
Journal:  Am J Clin Pathol       Date:  1992-11       Impact factor: 2.493

5.  Toward objective quality assurance in cervical cytopathology. Correlation of cytopathologic diagnoses with detection of high-risk human papillomavirus types.

Authors:  M E Sherman; M H Schiffman; A T Lorincz; M M Manos; D R Scott; R J Kuman; N B Kiviat; M Stoler; A G Glass; B B Rush
Journal:  Am J Clin Pathol       Date:  1994-08       Impact factor: 2.493

Review 6.  Cytokine modulation of immune defenses in cervical cancer.

Authors:  C H Evans; A A Flugelman; J A DiPaolo
Journal:  Oncology       Date:  1993 Jul-Aug       Impact factor: 2.935

7.  Human papillomavirus type 16 in cervical smears as predictor of high-grade cervical intraepithelial neoplasia [corrected].

Authors:  J Cuzick; G Terry; L Ho; T Hollingworth; M Anderson
Journal:  Lancet       Date:  1992-04-18       Impact factor: 79.321

8.  Relationship of human papillomavirus type to grade of cervical intraepithelial neoplasia.

Authors:  O Lungu; X W Sun; J Felix; R M Richart; S Silverstein; T C Wright
Journal:  JAMA       Date:  1992-05-13       Impact factor: 56.272

9.  Human papillomavirus DNA in women without and with cytological abnormalities: results of a 5-year follow-up study.

Authors:  E M de Villiers; D Wagner; A Schneider; H Wesch; F Munz; H Miklaw; H zur Hausen
Journal:  Gynecol Oncol       Date:  1992-01       Impact factor: 5.482

10.  Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types.

Authors:  A T Lorincz; R Reid; A B Jenson; M D Greenberg; W Lancaster; R J Kurman
Journal:  Obstet Gynecol       Date:  1992-03       Impact factor: 7.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.